Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options (Q30459034)

21 June 2017

title

Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options (English)

1 reference

21 June 2017

main subject

antibiotic resistance

0 references

antimicrobial resistance

1 reference

respiratory tract infection

inferred from title

1 reference

4

0 references

Markus Maeurer

Markus Maeurer

3

0 references

David Shu-cheong Hui

David S Hui

9

0 references

David W. Denning

David W Denning

7

0 references

Alimuddin Zumla

Alimuddin Zumla

1

0 references

Peter Mwaba

5

Peter Mwaba

1 reference

21 June 2017

2

Ziad A Memish

1 reference

21 June 2017

8

Frederick G Hayden

1 reference

21 June 2017

6

Jaffar A Al-Tawfiq

1 reference

21 June 2017

publication date

1 September 2014

1 reference

Lancet Infectious Diseases

21 June 2017

published in

1 reference

21 June 2017

volume

14

1 reference

21 June 2017

issue

11

1 reference

21 June 2017

page(s)

1136-1149

1 reference

Surveillance for emerging respiratory viruses

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

The rise of carbapenem resistance in Europe: just the tip of the iceberg?

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Interspecies transmission and emergence of novel viruses: lessons from bats and birds

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 20

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Determinants of antiviral effectiveness in influenza virus A subtype H5N1.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Intravenous peramivir for treatment of influenza in hospitalized patients.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical Trial

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Chloroquine is effective against influenza A virus in vitro but not in vivo

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Severe acute respiratory syndrome and coronavirus.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Use of convalescent plasma therapy in SARS patients in Hong Kong

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Invasive aspergillosis after pandemic (H1N1) 2009.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Rapid salvage treatment with virus-specific T cells for therapy-resistant disease

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Morpholino antisense oligomers: design, preparation, and properties

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Viral strategies of immune evasion

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Viral interference with antigen presentation to CD8 T cells: lessons from cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

T cell allorecognition via molecular mimicry

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Cytotoxic therapy for severe swine flu A/H1N1.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Emergence of Multiply Resistant Pneumococci

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Molecular characterization of Streptococcus pneumoniae invasive serotype 19A isolates from adults in two Spanish regions (1994–2009)

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Streptococcus pneumoniae: does antimicrobial resistance matter?

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Variation in definitions and isolation procedures for multidrug-resistant Gram-negative bacteria: a survey of the Society for Healthcare Epidemiology of America Research Network

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

New developments in carbapenems

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Current control and treatment of multidrug-resistant Acinetobacter baumannii infections

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

1 reference

7 January 2021

Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Determination of in vitro activities of polymyxin B and rifampin in combination with ampicillin/sulbactam or cefoperazone/sulbactam against multidrug-resistant Acinetobacter baumannii by the E-test and checkerboard methods.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Antibiotics in phase II and III clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Discovery and preclinical development of new antibiotics.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Advances in the development of new tuberculosis drugs and treatment regimens

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Tuberculosis drug discovery in the post-post-genomic era

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Hidden killers: human fungal infections

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Voriconazole resistance in Aspergillus fumigatus: should we be concerned?

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Novel immunologic classification of aspergillosis in adult cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

A dimorphic fungus causing disseminated infection in South Africa.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Use of oral fluconazole during pregnancy and the risk of birth defects

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Therapy for fungal diseases: opportunities and priorities

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Inhibition of Candida albicans virulence factors by novel levofloxacin derivatives

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Deaths due to respiratory tract infections in Africa: a review of autopsy studies

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016/S1473-3099(14)70828-X

7 January 2021

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

1 reference

12 December 2020

Progress and prospects for targeting Hsp90 to treat fungal infections

1 reference

12 December 2020

History of Swine influenza viruses in Asia

1 reference

12 December 2020

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

1 reference

12 December 2020

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza

1 reference

12 December 2020

Newer influenza antivirals, biotherapeutics and combinations

1 reference

12 December 2020

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation

1 reference

12 December 2020

Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients

1 reference

12 December 2020

Anti-inflammatory activity of macrolide antibiotics

1 reference

12 December 2020

Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Totally drug-resistant tuberculosis and adjunct therapies.

1 reference

12 December 2020

Signaling cascades as drug targets in model and pathogenic fungi

1 reference

12 December 2020

Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012.

1 reference

12 December 2020

Oral fluconazole during pregnancy and risk of birth defects

1 reference

12 December 2020

Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis

1 reference

12 December 2020

10.1016/S1473-3099(14)70828-X

Identifiers

DOI

1 reference

21 June 2017

1 reference